Stocktoria
Nkarta, Inc. NKTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-07-10
Nkarta, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | $0 |
| R&D expense | $90.4M | $96.7M | $96.8M | $90.9M | $63.4M |
| Operating income | -$122.0M | -$128.2M | -$131.7M | -$119.0M | -$86.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$104.1M | -$108.8M | -$117.5M | -$113.8M | -$86.1M |
| EPS (diluted) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 |
| Operating cash flow | -$88.7M | -$99.7M | -$86.2M | -$57.0M | -$67.9M |
| Free cash flow | -$89.9M | -$104.1M | -$114.3M | -$104.1M | -$73.0M |
| Cash & equivalents | $39.6M | $27.9M | $31.0M | $37.5M | $60.8M |
| Total assets | $404.2M | $501.2M | $378.9M | $472.9M | $273.9M |
| Total liabilities | $91.9M | $93.2M | $105.6M | $100.7M | $22.9M |
| Shareholders' equity | $312.3M | $408.0M | $273.3M | $372.2M | $251.0M |
Source: SEC EDGAR filings · CIK 0001787400 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.